December 2025 was a big month for announcements from Psithera Inc. The Watertown, Mass.-based newco announced its name change from Psivant Therapeutics, having come out from under the Roivant Sciences Ltd. umbrella – thus the dropping of the “-vant” name. The company also announced a $47.5 million series A financing and disclosed that Eric Shaff had started as the company’s new president and CEO. Read More
Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS focused on identifying and developing novel therapeutics for challenging targets in oncology by leveraging Insilico’s proprietary AI platform, Pharma.AI. Read More
Fibrobiologics Inc. has filed an IND application with the FDA seeking to begin first-in-human trials of CYPS-317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. Read More
In accordance with the publishing schedule, BioWorld Science was not published on Thursday, Jan. 1, 2026, or Friday, Jan. 2, 2026. Additionally, there will not be an issue published on Tuesday, Jan. 6, 2026. Read More
Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. Call us:
Americas: 855-258-3279
Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.
Innolake Biopharm (Hangzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies covalently bound to exatecan through a linker reported to be useful for the treatment of cancer. Read More
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG repeat expansion mutation in the coding region of the ATXN2 gene, which encodes ataxin-2. Read More
Researchers at Case Western Reserve University and their collaborators described the use of P7C3-A20, a compound that restores nicotinamide adenine dinucleotide (NAD+) homeostasis, as a potential strategy to reverse Alzheimer’s disease (AD) pathology in advanced Aβ- and tau-driven AD models. Read More
Haisco Pharmaceutical Group Co. Ltd. has synthesized G protein-coupled receptor GPR52 agonists reported to be useful for the treatment of psychiatric disorders. Read More
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising antibody or antigen-binding fragments linked to a cytotoxic drug through a linker reported to be useful for the treatment of atopic dermatitis. Read More
Hyloris Pharmaceuticals SA has entered into a license agreement with Arbormed Co. Ltd. for exclusive rights in Europe and Turkey to Arbormed’s novel injectable product candidate for Wilson’s disease. Read More
Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Read More
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin receptor antagonists reported to be useful for the treatment of neurological disorders. Read More
Excessive production of pro-inflammatory cytokines or aging-related chronic inflammation disrupts immunity and diminishes the efficacy of vaccines, although the underlying mechanisms remain unknown. Moreover, these pro-inflammatory cytokines are linked to adverse vaccine reactions. These two issues can lead to vaccine hesitancy, resulting in lower vaccination rates. Read More
